Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
The planned assessments include recording RTOG and NRS scores at time points T0 (starting treatment), T1, and T2 (end of treatment), documenting the time to complete re-epithelialization, any interruption of radiotherapy treatment, and collecting organizational and economic data for HTA and SWOT analyses.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female sex
Age ≥18 years
Histologically confirmed diagnosis of breast cancer, undergoing adjuvant radiotherapy after surgery and/or chemotherapy.
Onset of grade 2-3 radiodermatitis according to the RTOG scale, mainly located in the inframammary region, with or without axillary or supraclavicular extension.
Patients treated with a DACC-coated hydrogel device following a radiodermatitis diagnosis, between January 2023 and October 2025.
Treated on an outpatient basis with an advanced dressing protocol including:
* Cleansing with 0.05% sodium hypochlorite solution
* Application of DACC-coated hydrogel dressing, replaced every 2-3 days.
Complete clinical data available in outpatient records, including NRS and RTOG.
You may not be if
Grade 0 radiodermatitis (absence of skin toxicity)
Patients with incomplete clinical data or insufficient documentation for the purposes of retrospective analysis
Lack of availability of minimum clinical follow-up until complete re-epithelialization
Clareo Health | Retrospective Observational Study on the Use of Advanced Bacterial-binding Dressings (DACC-coated Hydrogel Dressings) in Radiodermatitis
